ECX — Epigenomics AG Share News
0.000.00%
Last trade - 00:00- €0.61m
- -€2.62m
- €0.49m
Brief: Epigenomics AG expects 2017 revenues to be in range of Euro 1 mln to Euro 1.5 mln
Brief: Epigenomics board recommends acceptance of voluntary public takeover offer
Brief: Epigenomics Q1 net loss shrinks to EUR 2.4 mln
Brief: Epigenomics FY 2016 total revenue up by 102 pct to 4.2 mln euros
Brief: Blitz F16-83 GMBH to launch takeover offer for Epigenomics AG
Brief: Epigenomics: ADMIT study results published in journal Cancer Treatment and Research Communications
Brief: Epigenomics issues new shares by way of private placement
Brief: Epigenomics Q3 revenue up 83 pct at 0.9 million euros
Brief: Epigenomics issues new shares by way of private placement
Brief: Epigenomics Q2 net loss widens to 3.3 mln euros
Brief: Epigenomics: draft registration statement for potential U.S. public offering of ADSs
Brief: Epigenomics: Gregory Hamilton appointed as CEO
Brief: Epigenomics: Epi Procolon included in newly issued USPSTF guidelines for colorectal cancer screening
Brief: Epigenomics issues new shares by way of private placement
Brief: Epigenomics Q1 net loss widens to EUR 4.3 million
Brief: Epigenomics announces commercial launch of Epi proColon in U.S.
Brief: Epigenomics receives FDA approval for Epi proColon
Brief: Epigenomics enters agreement with Biochain on lung cancer test for China
Brief: Epigenomics FY 2015 total revenue up by 38 pct to 2.1 mln euros